Key facts
- Notable investors include ANRI, Intellectual Property Acceleration Program for Startups, Delight Ventures, Coral Capital., Gogin Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Cosomil
- ·The full record, as it builds
Funding rounds
No funding rounds for Cosomil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cosomil
Developer of a liquid-based diagnostic technology designed to offer early disease diagnosis and support for drug development. The company uses single enzyme activity-based protein profile technology, which detects enzyme activity with ultra-high sensitivity at the single molecule level using fluorescent probes and microdevices, enabling the medical system to provide early and accurate diagnosis of diseases, which can lead to improved patient outcomes.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Employees
- 50
- Website
- cosomil.com/
- Ownership
- Privately Held (backing)
Cosomil doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cosomil shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cosomil in its N-PORT filings yet. We sweep new filings monthly.